Selling a Healthcare Business Post-COVID UK 2026

UK healthcare M&A has settled into a new normal in 2026, and the rules for selling a healthcare business now look almost nothing like they did in the 2020 to 2022 boom. Volumes have stabilised, valuation multiples have moderated from peak, regulatory scrutiny has tightened sharply, and buyer behaviour is far more disciplined. For UK owners of care home groups, dental practices, GP and primary care surgeries, veterinary practices, and medispas thinking about an exit, the post-COVID landscape rewards a fundamentally different preparation strategy than the one that worked five years ago.

This article sets out what has actually changed, what the 2026 buyer landscape looks like across the main UK healthcare sub-sectors, where current multiples sit, and how owners should adapt their exit strategy. If you operate in residential care, our care homes M&A advisory page covers our sector-specific work, with equivalent pages for dental, medispas and veterinary.

The Five-Year Reset: From Boom to Discipline

Between 2019 and 2022, UK healthcare M&A ran hot. Pandemic-era capital availability, ultra-low interest rates, and a flight to defensive sectors drove aggressive bidding, particularly in residential care, dental, primary care and veterinary. By 2023 and 2024, conditions tightened materially. Rising interest rates, constrained credit, and a tougher cost base in care (staff, agency, energy, food) reset both deal volumes and valuation methodology.

Arnall Golden Gregory's April 2026 analysis captures the change cleanly. Buyer tolerance for EBITDA add-backs has compressed from approximately 20% of EBITDA in the peak years to a more constrained 12% to 15%. Documentation requirements have stepped up. Diligence focuses on cash conversion and revenue consistency rather than growth narratives. The pricing model that was driven by projections and synergies has given way to one grounded in demonstrated performance.

This matters because many owners are still benchmarking against 2021 transaction precedents. In 2026, those precedents are no longer the operative range.

UK Healthcare M&A in 2025 and 2026: The Numbers

According to Heligan Group's UK Healthcare M&A Review for 2025, UK healthcare M&A totalled 280 announced or completed deals in 2025, broadly flat year on year. While UK M&A across most sectors declined by 10% to 15% versus 2024, healthcare outperformed, confirming its status as a defensive, structurally supported sector. Sub-sector breakdown in 2025:

• Health and social care: 47% of total UK healthcare deal volume
• Pharma and life sciences: 22%
• Medical equipment and devices: 17%
• Healthcare IT: 15%

Strategic buyers accounted for 83% of UK healthcare deals in 2025. Private equity remained selective but engaged, focusing on platform investments above the £3m EBITDA threshold and accretive bolt-ons to existing platforms. Strategic dominance reflects both the operating environment (synergy-driven buyers can underwrite higher prices than financial sponsors when leverage is expensive) and the maturity of UK platform consolidation in care, dental and veterinary.

QuantPillar's 2025 to 2026 valuation guide reports median healthcare services EV/EBITDA moderating to approximately 11.5x in 2026, down from 14.5x in the prior year. The pattern is consistent: quality assets continue to clear, but at more disciplined multiples than in the boom.

Sub-Sector by Sub-Sector: Where Multiples Sit in 2026

The headline multiple matters less than understanding how it splits by quality, scale, and sub-sector. UK and US benchmarks consistently show a 2 to 4 turn premium for platform-scale assets over sub-scale add-ons. The picture by sub-sector:

Care Homes

Christie & Co's 2025 Care Market Review recorded a record 12 months to July 2025 for UK care home deals. Overseas capital drove a meaningful share of volume, with sector-specialist REITs Welltower and Omega leading large acquisitions including Care UK and 45 Four Seasons care homes. H1 2025 also saw the Care Trust REIT acquisition of Care REIT plc and the Aedifica-Cofinimmo merger. Rising private fee levels and easing inflation have lifted EBITDA, while leasehold OpCo multiples are increasingly used as a benchmark, with WholeCo valuations supported as a result.

For SME operators who paused acquisitions through the pandemic, cost stabilisation and improving trading have reignited bolt-on appetite. Competition for prime consented development sites in H1 2025 reached a record high at Christie & Co. The current regulatory factor to weigh: in February 2026 the CMA imposed Initial Enforcement Orders on four Welltower acquisitions covering over 600 UK care homes, with Phase 1 merger review running from 10 March to 8 May 2026, according to Proskauer. Owners planning a sale to a large consolidator should factor regulatory clearance timing into their exit timeline.

Dental

The UK dental sales market in 2026 is defined by two parallel forces: an NHS contract reset effective 1 April 2026 and an active CMA market study launched in March 2026. The Practice Plan 2026 Dental Sales Market analysis frames it directly: dental buyer behaviour has shifted to reward private and mixed practices over those with high NHS dependency. The BBC reported in March 2026 that over £900m has been refunded to the NHS in two years for missed activity, with more than 40% of dentists returning money in both years.

The CMA market study, outlined by Proskauer, pays particular attention to prices and profitability, conduct of private dental practices, and implications for consumer choice. Average prices charged by larger PE-backed dental groups are approximately 18% higher than those of independent practices, according to SML Law's UK PE in Professional Practices report. Owners need to factor potential regulatory remedies into their valuation models.

US DSO benchmarks from FOCUS Investment Banking's Healthcare Services 2026 Multiples report show approximately 9x to 11x EBITDA for multi-location groups and approximately 5x to 8x for single-site or sub-£1m EBITDA practices. UK figures sit somewhat below these levels for similar profiles but follow the same pattern, with multi-office density, hygiene recall programmes, and private payor mix driving the upper end of the range.

Veterinary

UK veterinary remains a strategically active sector but operates under the most intense regulatory scrutiny in UK healthcare M&A. The CMA's final report on the market investigation into veterinary services for household pets, published on 24 March 2026, included final remedies covering price lists, prescription fee caps, a price comparison website, and disclosure of whether the practice is part of a larger corporate group. Implementing Orders will be issued in the next six months, with most remedies coming into force over the following 3 to 12 months.

For owners, the regulatory shift creates a more transparent but less unilaterally pricing-led market. The strategic interest remains, with Vetopia entering the UK market in 2026 through its VetThing brand, bringing employee ownership economics into the buyer mix. Veterinary practice multiples in QuantPillar's 2026 data sit in the 8x to 14x range, with multi-location scale and specialty services driving the upper end. Existing buyers IVC Evidensia, Medivet, CVS Group and VetPartners remain active, alongside Vetopia and an increasing number of international entrants.

Primary Care and GP Surgeries

GP practice consolidation continues but at a more measured pace than 2021 to 2022. The 2024 to 2025 NHS contract reset, regulatory complexity, and rising staff costs have tempered buyer enthusiasm. Strategic buyers focused on multi-site networks and accretive bolt-ons dominate. EBITDA multiples for single-site practices sit in the mid-single-digit range, with diversified multi-site groups commanding turns above that.

Medispas and Aesthetics

Aesthetic services remain one of the most active sub-sectors. FOCUS Investment Banking reports US medical spa multiples at approximately 7x to 12x for scaled multi-state brands and 3x to 8x for single-site or early-growth chains. UK medispa multiples follow a similar pattern, with membership and subscription revenue models commanding the upper end. The 2026 CQC re-registration process and tightening regulation around prescription-only medication creates a barrier to entry that benefits compliant operators preparing for sale.

For owners scoping how a sophisticated buyer will assess their business inside a healthcare exit, our buy-side advisory page sets out the diligence standards applied by PE-backed platforms and strategic buyers across UK healthcare.

What Has Actually Changed Since 2021

Five shifts define the post-COVID UK healthcare M&A market, and each one changes how a seller should prepare.

1. Add-Back Discipline

Buyers will accept far fewer EBITDA add-backs than they did three years ago. The constrained 12% to 15% of EBITDA range is now standard, against approximately 20% in the peak. Owner remuneration, one-off COVID costs, agency staffing premiums, and discretionary spend are scrutinised line by line. Owners preparing for sale should commission a vendor-side Quality of Earnings exercise that uses 2026 buyer standards rather than 2021 norms.

2. Cash Conversion and Documentation

EBITDA-to-cash conversion has become a primary diligence focus. Sponsors and strategics alike are running 13-week cash flow analysis on the trailing 24 months, looking for working capital volatility, accrued income build-up, and creditor stretch. Documentation is expected in the data room from week one, not assembled reactively in diligence.

3. Regulatory Risk Is Priced

The CMA's active engagement in veterinary, dental and care has changed how buyers price regulatory exposure. Sponsors are now modelling the cost of remedies (price caps, transparency mandates, divestments) into their bid math. Owners with practices in concentrated local catchments where serial acquisitions have reduced competition are facing tougher questions.

4. NHS and Public Payor Dependency Is a Multiple Drag

The £900m NHS dental refunds reported by the BBC have crystallised what buyers had long suspected: NHS dependency is now a meaningful multiple drag for practices that cannot demonstrate consistent activity delivery. Private and mixed practices, with controllable revenue and pricing power, command premiums over NHS-heavy practices. The same logic increasingly applies to GP and primary care assets exposed to PCN funding volatility.

5. Quality Sells, Quantity Stalls

Heligan's 2025 review notes that activity is increasingly concentrated in high-quality assets. K-shaped valuation outcomes have become the norm: top-quartile assets see multiple expansion while sub-scale or sub-quality assets struggle to attract competitive bids and accept discounts of 1 to 2 turns on the standalone multiple.

The 2026 Buyer Universe for UK Healthcare

The active buyer landscape has rebalanced. Strategic dominance at 83% of 2025 deal volume tells one story; private equity selectivity tells another. The current categories of buyer for UK healthcare assets are:

• Sector-specialist REITs and overseas capital. Welltower, Omega, Care Trust REIT, Aedifica-Cofinimmo. Drove some of the largest 2025 UK care home deals.
• Established UK consolidators. HC-One, Barchester, Four Seasons, Care UK in care homes. IVC Evidensia, Medivet, CVS Group, VetPartners in veterinary. Bupa Dental, Mydentist, Portman Healthcare, Rodericks, Dental Partners in dental. Active for both platform-level moves and ongoing bolt-ons.
• Mid-market UK and European PE platforms. Inflexion, Apposite Capital, Palatine, Limerston, August Equity, Vespa Capital. Continue to back platform investments above £3m EBITDA.
• International new entrants. Vetopia (veterinary) in 2026 is the latest example of a European group entering the UK market through a defined brand and acquisition pipeline. Expect more international entry across dental and aesthetics.
• Family offices and patient capital. Particularly active in care homes, where the lease-based OpCo model and steady cash flow profile suit long-duration capital.
• Healthcare conglomerates and infrastructure funds. For larger transactions, including health system tie-ups, ambulatory infrastructure, and tech-enabled services.

The implication for sellers is that a competitive process needs to surface bidders from at least three of these categories to test the full valuation range.

Tax Timing: BADR and the April 2026 Rate Change

Business Asset Disposal Relief moved to an 18% Capital Gains Tax rate from 6 April 2026, alongside changes to Inheritance Tax Business Property Relief. Our BADR April 2026 analysis covers the implications in detail. For UK healthcare owners, two practical points matter most. First, the rate change is now embedded; owners should not delay or accelerate a sale solely on tax timing without a full advisor-led net proceeds model. Second, the BADR lifetime limit and qualifying conditions remain in scope and continue to favour share sales over asset sales, structured to preserve relief access.

Process Discipline in 2026: How to Run a Sale That Lands

A 2026 UK healthcare sale process that lands at a premium multiple typically runs over 9 to 14 months from advisor engagement to completion. The four phases:

Phase 1: Preparation (Months 1 to 3)

• Normalised EBITDA build using 2026-tight add-back standards
• Vendor-side Quality of Earnings exercise where deal size justifies it (typically EBITDA above £1m)
• Cohort analysis on revenue, with residency length, payor mix, recall, and retention metrics
• Regulatory register confirming CQC ratings, GDC registrations, RCVS registrations, NHS contract status, and any open investigations
• Information memorandum and data room build
• Long list of qualified buyers in the categories above

Phase 2: Marketing and Indicative Bids (Months 4 to 5)

• Teaser distribution and NDA execution
• Information memorandum distribution
• Management presentations to qualified buyers
• Indicative offers (IOIs) received and benchmarked

A well-run healthcare process targeting a £1m to £5m EBITDA business should generate 5 to 12 IOIs from a thoughtful buyer list. The spread between highest and lowest is typically 25% to 40%, which is why running competitive process discipline matters.

Phase 3: Diligence and Definitive Agreement (Months 6 to 11)

• Exclusivity with one buyer
• Confirmatory diligence across financial, legal, regulatory, commercial, operational, HR/payroll, and IT/cyber workstreams
• SPA drafting and negotiation
• Reps and warranties insurance underwriting where applicable

Diligence in UK healthcare adds workstreams that generalist sectors do not require: CQC inspection history, GDC and RCVS professional standing, NHS contract reconciliation (where applicable), safeguarding records, clinical incident registers, and historic medical insurance claims.

Phase 4: Signing, Completion, and Post-Closing (Months 12 to 14)

• Signing and completion (often simultaneous for clean structures)
• Stamp duty submission and Companies House updates
• Regulatory notifications to CQC, GDC, RCVS, NHS England as applicable
• Working capital and net debt adjustments within 60 to 90 days
• W&I insurance claims period of typically 24 months for general warranties, 7 years for tax

Six Levers That Move the Multiple in 2026

Looking across recent UK healthcare transactions, the six levers that consistently lift entry multiples are:

1. Documented audit-quality financials with 2026-standard add-backs. Eliminates the largest source of price erosion in confirmatory diligence.
2. Strong private payor mix. For dental and GP, private and mixed practices command premiums over NHS-heavy practices. For care, private fee-paying density commands a premium over local authority dependency.
3. Clinician retention and contracted notice periods. Buyers underwrite continuity of clinical staff explicitly. Notice periods of 6 to 12 months for partners and senior clinicians are standard.
4. Clean regulatory register. CQC Good or Outstanding ratings, current GDC and RCVS registrations, no open NHS contract reconciliation disputes.
5. Geographic density that fits a platform integration plan. Sub-scale practices with 10 to 15 mile catchment overlap with an existing consolidator command 1 to 2 turns of premium.
6. Reduced founder and clinician-owner dependency. Documented succession plans, distributed clinical responsibility, and proof the business operates without the owner-clinician are foundational.

Frequently Asked Questions

Are post-COVID UK healthcare multiples lower than 2021 peak?

Yes. QuantPillar reports median healthcare services EV/EBITDA at approximately 11.5x in 2026, down from 14.5x the prior year. Multiples remain healthy by historical standards but are no longer at 2021 peak. Quality assets continue to clear at the upper end of the range; sub-scale or compliance-impaired assets trade at the lower end.

Should I surrender my NHS dental contract before selling?

It depends on activity delivery, private payor mix, and buyer profile. Henry Schein Dental Practice Sales notes the answer is no longer a simple no. Buyers focused on private dental groups may pay a premium for a fully private practice. Buyers building mixed-platform models may pay a premium for retained NHS contract value where activity delivery is strong. The decision belongs in advisor-led modelling, not as an ad-hoc choice ahead of a sale.

How long does CMA clearance typically take for UK healthcare M&A?

Phase 1 merger reviews run approximately 8 weeks under the CMA process. Phase 2 in-depth investigations add several months. For the current Welltower care home transactions, Phase 1 review runs from 10 March to 8 May 2026, tracked by Proskauer. Owners planning a sale to a large consolidator should factor clearance timing into deal completion expectations.

What EBITDA threshold attracts UK PE platform interest?

Most active UK healthcare PE platforms target tuck-ins at £500k to £3m EBITDA and platform investments at £3m to £15m EBITDA. Below £500k, the buyer pool narrows to local or regional consolidators rather than national platforms.

Has private equity left UK healthcare?

No. PE remains active but more selective. Heligan's 2025 review notes that while PE is more selective, strategic buyers are increasingly active, particularly in bolt-on acquisitions. The PE thesis on UK healthcare remains intact, supported by demographic tailwinds, defensive demand and predictable cash generation.

Plan the Exit Around Demonstrated Performance

The owners who get the strongest outcomes from a UK healthcare exit in 2026 are running a different playbook than the one that worked in 2021. They are building documented audit-quality financials, demonstrating revenue consistency and cash conversion, surfacing regulatory exposure proactively rather than reactively, and running competitive processes that test the full buyer universe. They are not relying on growth narratives, aggressive add-backs, or 2021 transaction precedents.

If you are scoping an exit from a UK healthcare business in the next 12 to 24 months and want a confidential view on realistic 2026 multiples for your sub-sector, the live buyer landscape, and how to position your business for a competitive process, contact our team. We work exclusively with owners of UK healthcare and building services businesses and will give you an evidence-based view on the path that maximises your outcome.

Your Advisory Team

Experienced Dealmakers Lead Your Exit

Every exit is led by a senior advisor who has been through it themselves. Meet the team who will guide you.

Joe Lewin

Founder & Lead Advisor — M&A Specialist

• •4 years in M&A advisory; 22 completed transactions
• •Direct relationships with hundreds of strategic and financial acquirers
• •Raised £2m in funding; placed 3rd of 1,900 at OnStage (the "Y Combinator of Europe")
• •Previously built a mobility and field services business to 30 staff and 6 UK warehouses, then sold via competitive process with an EY M&A partner
• •Full-stack developer of advanced agent systems and second-brain tooling for the M&A process

Joe Thomason

Senior M&A Advisor

• •Previously Analyst at KBS Corporate
• •Analyst at Hampleton Partners, Associate at Tech Credit Partners
• •Worked on 25+ completed transactions (£300k to £120m)
• •Specialist in debt lending for business buyers

Emerson Patton

Sector Specialist: Building, Construction & Trade Services

• •20+ years advising owners in building services, fire safety, HVAC, plumbing, and construction
• •Guided 200+ companies through growth, profit improvement, and exit planning
• •Builds equity value and operational structure long before a sale
• •Partners with DFA to prepare owners for exit while the advisory team runs the sale

Sam Pouyan

Senior M&A Advisor

• •10 years across buy-side and sell-side M&A
• •Former investment banking analyst
• •Expert in financial modelling and deal structuring

James Duboullay

Senior M&A Advisor

• •25+ years across investment banking, M&A and fundraising
• •Sector focus: essential services and software
• •Long-standing relationships with private equity buyers and growth funds
• •Personally advising DealFlowAgent founders for the past four years

Sage

AI Deal Concierge

• •Available 24/7. Monitors every signal in your deal
• •Keeps your advisory team one step ahead at all times
• •Trained on thousands of M&A transactions

Sterling

Buy-Side Deal Origination Agent

• •Engages 12,000+ acquirers to surface live mandates and intent
• •Qualifies buyer fit, budget and timing before introductions
• •Feeds your advisory team with warm, ranked buyer matches

Tim Armoo

Partner & Chief Marketing Officer

• •Founded Fanbytes, scaled revenues to £10m+, exited at multi-eight-figure valuation
• •Advises on multiple M&A deals, invests in early-stage ventures
• •Built 700,000+ follower community teaching founders to scale and sell
• •Partnered with DealFlowAgent to expand access for founders to buyers

Assigned Per Deal

Sector Expert

Industry-Specific M&A Advisor

For every deal, our advisory team includes a sector specialist from that client's specific industry and niche: bringing relationships, insider knowledge, and leverage to support your process and achieve the best acquisition outcome.

Healthcare M&A Specialists

Thinking of selling your healthcare business?

DealFlowAgent is the UK and US's only M&A advisory firm specialising in healthcare businesses. Our trusted advisors leverage industry knowledge, buyer relationships and proprietary technology to help business owners secure multiple acquisition offers at higher valuations.

Talk to a Real Advisor - No Obligation

Speak with Joe or Sam about your situation. No hard sell, no commitment, just honest advice from advisors who've been through it.

What's Your Business Actually Worth?

Our valuation tool gives you a realistic range based on recent comparable transactions in your sector. Takes 3 minutes.

Related Articles